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Patient Characteristics in
Cardiogenic Shock Studies
Differences Between Trials and Registries
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Allison Dupont, MD,d Srihari Naidu, MD,e Magnus Ohman, MD,f L. Christian Napp, MD,g William O’Neill, MD,a
Mir B. Basir, DOa

ABSTRACT
OBJECTIVES This study sought to evaluate the differences in cardiogenic shock patient characteristics in trial patients
and real-life patients.
BACKGROUND Cardiogenic shock (CS) is a leading cause of mortality in patients presenting with acute myocardial
infarction (AMI). However, the enrollment of patients into clinical trials is challenging and may not be representative of
real-world patients.
METHODS We performed a systematic review of studies in patients presenting with AMI-related CS and compared
patient characteristics of those enrolled into randomized controlled trials (RCTs) with those in registries.
RESULTS We included 14 RCTs (n ¼ 2,154) and 12 registries (n ¼ 133,617). RCTs included more men (73% vs 67.7%,
P < 0.001) compared with registries. Patients enrolled in RCTs had fewer comorbidities, including less hypertension
(61.6% vs 65.9%, P < 0.001), dyslipidemia (36.4% vs 53.6%, P < 0.001), a history of stroke or transient ischemic attack
(7.1% vs 10.7%, P < 0.001), and prior coronary artery bypass graft surgery (5.4% vs 7.5%, P < 0.001). Patients enrolled
in RCTs also had lower lactate levels (4.7  2.3 mmol/L vs 5.9  1.9 mmol/L, P < 0.001) and higher mean arterial
pressure (73.0  8.8 mm Hg vs 62.5  12.2 mm Hg, P < 0.001). Percutaneous coronary intervention (97.5% vs 58.4%,
P < 0.001) and extracorporeal membrane oxygenation (11.6% vs 3.4%, P < 0.001) were used more often in RCTs.
The in-hospital mortality (23.9% vs 38.4%, P < 0.001) and 30-day mortality (39.9% vs 45.9%, P < 0.001) were lower
in RCT patients.
CONCLUSIONS RCTs in AMI-related CS tend to enroll fewer women and lower-risk patients compared with registries.
Patients enrolled in RCTs are more likely to receive aggressive treatment with percutaneous coronary intervention and
extracorporeal membrane oxygenation and have lower in-hospital and 30-day mortality.
(J Am Coll Cardiol Intv 2022;15:297–304) © 2022 by the American College of Cardiology Foundation.
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ing recruitment into RCTs stem from challenges with
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ABBREVIATIONS

informed

hemodynamically

Our main objective was to describe and compare

AND ACRONYMS

compromised patients and investigators’ be-

baseline characteristics of patients in RCTs and regis-

liefs and biases about a potential lack of equi-

tries. All baseline variables were compared between

poise between treatment modalities.4 With

both groups. When analyzing speciﬁc treatment vari-

only a small number of RCTs having been

ables that were reported as outcomes (eg, multivessel

infarctionLrelated cardiogenic

performed, varying inclusion criteria, and

percutaneous

shock

heterogeneity in shock severity, it may be

excluded RCTs dedicated to investigating that speciﬁc

CS = cardiogenic shock

challenging to generalize the results of such

treatment to avoid bias. For example, we excluded the

ECMO = extracorporeal

trials to all comers. We sought to evaluate

CULPRIT-SHOCK (Culprit Lesion Only PCI versus

membrane oxygenation

the differences between patients enrolled in

Multivessel PCI in Cardiogenic Shock) trial when

MCS = mechanical circulatory

RCTs compared with patients enrolled in

reporting multivessel PCI as an outcome. 7 Categoric

contemporary registries.

variables were compared using the chi-square test,

AMI = acute myocardial
infarction

AMICS = acute myocardial

support

consent

in

PCI = percutaneous coronary
SEE PAGE 305

intervention

RCT = randomized controlled
trial

METHODS

coronary

intervention

[PCI]),

we

whereas continuous variables were compared using
the 2-sample t-test. For mortality outcomes, we performed a pooled analysis using the following metaanalysis method. We ﬁrst input the total clinical

SEARCH STRATEGY. We conducted a systematic re-

setting percentage for the main outcome and the

view of studies that included patients with AMICS.

number of participants of each study and then calcu-

We performed a computerized search according to the

lated the corresponding 95% CIs using the normal

proposal for conducting and reporting Meta-analysis

approximation to the Poisson distribution. Then, we

of Observational Studies in Epidemiology 5 and the

pooled effect sizes, which denoted median “rates” and

Preferred Reporting Items for Systematic Reviews

the 95% CIs using the inverse variance method with

and Meta-Analyses guidelines. 6 We performed a sys-

random effects. We performed the analysis to estimate

tematic search limited to the English language

the 95% CIs of mortality rates. However, we still

through the MEDLINE, Embase, and Cochrane data-

compared both groups using the chi-square test for

bases from January 2005 to July 2021 using the

proportions given the invalidity of comparing 2 me-

following search terms separately and in combina-

dians with the 95% CIs without patient-level data. The

tion: “cardiogenic shock,” “randomized controlled

characteristics

trial,” “registry,” “CS,” and “shock.” We screened the

weighted according to the sample size. To further

retrieved studies’ bibliographies and previous re-

evaluate the patients enrolled in the most recent RCTs,

views for any relevant studies not found through the

we performed a sensitivity analysis including the 6

and

outcomes

presented

were

initial search. The search was performed by 2 inde-

most recently published RCTs from 2017 onward 8–13

pendent investigators (K.B. and M.M.) who are both

and compared them with registries that enrolled pa-

physicians. We included all RCTs that included pa-

tients within the same time frame. 3,14–18

tients with AMICS during our study period. Our

We also evaluated the trend of enrolling women

strategy was to compare patients enrolled in RCTs, of

in the included RCTs using the ﬁrst year of enroll-

which the data are used to form current clinical

ment rather than publication year. Trend analysis

practice guidelines to contemporary real-world pa-

was

tients. To ensure that we included a representative

method. A P value #0.05 was considered statisti-

performed

using

the

Poisson

regression

sample of contemporary patients in the comparison,

cally signiﬁcant. Statistical analysis was performed

we opted to include only recent large registries. We

using STATA software for Windows version 17.0

included registries published in 2012 onward that

(StataCorp LLC).

enrolled >1,000 patients. The rationale for choosing
large registries was that they would better represent

RESULTS

patients than smaller registries that might originate
from a single or a few regional centers, introducing

We included 14 RCTs and 12 registries in our study.

selection bias. The data were extracted by 2 inde-

Details

pendent investigators (K.B. and M.M.). We did not

Supplemental Table S1. RCTs included a total of 2,154

include registries with duplicate or overlapping co-

patients, and their publication dates ranged from 2005

horts. The detailed search strategy and ﬂowchart of

to 2020. Most of the trials were performed in Europe,

the study are shown in Figure 1. The study is a meta-

except 1 study that included centers in North Amer-

analysis, and Institutional Review Board approval

ica.19 Of the 14 RCTs, 7 aimed to evaluate mechanical

was not required.

circulatory

on

the

included

support

(MCS)

RCTs

are

shown

devices.8,11,20–24
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revascularization strategy in the included RCTs

F I G U R E 1 Flowchart of the Included Studies

was predominantly PCI with a small percentage of
coronary artery bypass graft surgeries. The exclusion
criteria of RCTs are also shown in Supplemental
Table S1. Most studies excluded patients who were
determined to be moribund due to prolonged resuscitation or severe comorbid conditions. Most of the
left ventricular assist device trials excluded patients
with right ventricular failure. Studies in which 1
randomization arm included intra-aortic balloon
pumps also excluded patients with severe aortic
regurgitation.
Details on the included registries are listed in
Supplemental Table S2. Registries included 133,617
patients published from 2012 to 2021. MCS use was
predominantly intra-aortic balloon pumps in earlier
studies but incorporated other devices in later publications, as shown in Supplemental Table S2. The
largest registries included were from the CathPCI
Registry (accounting for about one-half of the cohort,
56,497 patients from 2005 to 2013) 25 followed by a
studies from both the CathPCI Registry and the Chest
Pain Registry (28,304 patients from 2015 to 2017), 18
the Japan-PCI Registry (n ¼ 17,549),15 and the IQ
registry (n ¼ 15,259).26 The most common access site
used was the femoral access (91.3%).
COMPARISON BETWEEN RCTs AND REAL-WORLD
REGISTRIES. Differences in baseline characteristics

AMI-CS ¼ acute myocardial infarction-related cardiogenic shock; RCTs ¼ randomized

between patients included in RCTs and registries are

controlled trials.

listed in Table 1. Patients in RCTs were more likely to
be men (73% vs 67.7%, P < 0.001). Patients included
in RCTs had fewer comorbidities, including less hypertension (61.6% vs 65.9%, P < 0.001), dyslipidemia
(36.4% vs 53.6%, P < 0.001), smoking (32.9% vs
38.8%, P < 0.001), history of stroke or transient
ischemic attack (7.1% vs 10.7%, P < 0.001), and history of coronary artery bypass graft surgery (5.3% vs
7.5%, P < 0.001). Patients included in RCTs were less
likely to present with ST-segment elevation myocar-

The percentage of women enrolled in RCTs was low,
ranging

between

7.1%

and

37%

(Supplemental

Table S4). There was no signiﬁcant change in the
trend of enrolling women in RCTs over the years from
2000 to 2015 (P trend ¼ 0.156) (Supplemental
Figure S1).
DIFFERENCES IN TREATMENT MODALITIES AND

dial infarction (72.4% vs 79.3%, P < 0.001) and more

MORTALITY. PCI (95.8% vs 58.4%, P < 0.001), mul-

likely to have a lower body mass index (26.8  2.0

tivessel PCI (31% vs 27.4%, P < 0.001), and extracor-

kg/m 2 vs 28.6  6.3 kg/m 2, P < 0.001), lower lactate

poreal membrane oxygenation (ECMO) (11.6% vs

levels (4.7  2.3 mmol/L vs 5.9  1.9 mmol/L,

3.4%, P < 0.001) were used more often in RCT pa-

P < 0.001), and higher mean arterial blood pressure at

tients, whereas G2b3a inhibitors were used less often

presentation (73.0  8.8 mm Hg vs 62.5  12.2 mm Hg,

in

P < 0.001).

P < 0.001). The in-hospital mortality (23.9% [95% CI:

patients

enrolled

in

RCTs

(26.7%

vs

41%,

The sensitivity analysis results comparing the pa-

18.0%-29.9%] vs 38.4% [95% CI: 29.2%-47.5%],

tients’ baseline characteristics between the recently

P < 0.001) and 30-day mortality (39.9% [95% CI:

published

in

33.1%-46.6%] vs 45.9% [95% CI: 33.0%-58.9%],

Supplemental Table S3. The differences between both

P < 0.001) were lower in patients enrolled in RCTs

groups were concordant with the overall analysis,

compared with real-life registry patients (Table 1,

with the patients enrolled in RCTs more likely to be

Figure 2). A summary of the study results is shown in

men with fewer comorbidities.

the Central Illustration.

registries

and

RCTs

are

shown
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T A B L E 1 Comparison of Baseline Characteristics and Treatment Modalities Based on

Study Type

The major challenge in conducting RCTs in CS is an
ethical dilemma when attempting to enroll unstable
patients. Physicians must believe in the equipoise of

14 RCTs
(n ¼ 2,154)

12 Registries
(n ¼ 133,617)

P Value

intended treatment and be willing to randomize patients when comparing therapies. They must also be

Baseline characteristics and
hemodynamic parameters

willing to have some treatment delay while consent is

Age, y

67.5  7.0 [2,109]

66.1  12.9 [129,951]

<0.001

obtained from the patient or family. The risk of po-

BMI, kg/m2

26.8  2.0 [1,633]

28.6  6.3 [86,517]

<0.001

tential selection bias in the sickest patients can then

73.0

67.7

<0.001

lead to the enrollment of a lower-risk population.

61.6 [2,141]

65.9 [118,358]

<0.001

This results in the exclusion of patients who may

Diabetes, %

32.4

32.2 [118,358]

0.862

beneﬁt most from intended therapies and lead to the

Smoking, %

33.3 [2,084]

38.8 [90,054]

<0.001

need for an increased sample size. In our analysis,

Dyslipidemia, %

36.4 [1,560]

53.6 [115,366]

<0.001

patients enrolled in RCTs had fewer comorbidities,

Previous MI, %

21.3 [2,080]

21.6 [118,358]

0.762

Previous PCI, %

18.8 [1,488]

20.4 [114,889]

0.136

Previous CABG, %

5.3 [1,844]

7.5 [112,799]

<0.001

History of CVA or TIA, %

7.1 [1,861]

10.7 [90,183]

<0.001

11.4 [1,408]

8.7 [112,614]

<0.001

LVEF

31.8  6.2 [1,912]

38.6  14.4 [32,147]

<0.001

Mean arterial pressure

73.0  8.8 [1,510]

62.5  12.2 [1,716]

<0.001

Male, %
Hypertension, %

Peripheral vascular disease, %

STEMI, %
Lactate
Out-of-hospital arrest/
resuscitation

had lower lactate levels, were less likely to present
with ST-segment elevation myocardial infarction, and
had lower mortality rates suggestive of a lower-risk
cohort.
Patients enrolled in RCTs also received more
aggressive treatment with revascularization and
ECMO. To date, the only therapy demonstrating efﬁ-

72.4 [1,292]

79.3 [112,625]

<0.001

4.7  2.3 [760]

5.9  1.9 [1,716]

<0.001

cacy in an AMICS RCT is early revascularization.27 Our

49.7 [2,008]

32.0 [52,651]

<0.001

analysis demonstrates a higher rate of revascularization with PCI in RCT compared with registry patients

Procedural characteristics

(97.5% vs 58%). Our analysis suggests that RCT pa-

PCI, %

97.5 [2,031]

58.4 [8,551]

<0.001

tients are less sick and more likely to receive

Thrombolysis, %

6.2 [1,328]

4.1 [91,636]

<0.001

aggressive treatment.

Multivessel PCI

31.0 [805]

27.4 [64,106]

0.025

As clinicians relying on evidence-based practices,

CABG, %

2.5 [1,927]

2.0 [26,260]

0.156

the gold standard of which are RCTs, we must excerpt

GP2b3a inhibitor, %

26.7 [1,888]

41.0 [8,885]

<0.001

Mechanical ventilation, %

80.6 [1,394]

54.2 [5,806]

<0.001

11.61 [739]

3.4 [1,716a]

<0.001

23.9 (18.0-29.9) [279]

38.4 (29.2-47.5) [91,452]

<0.001

39.9 (33.1-46.6) [2,045]

45.9 (33.0-58.9) [6,835]

<0.001

ECMO use
In-hospital mortality, %
30-day mortality, %

Values are mean  SD, %, or % (95 CI). Numbers in brackets represent the number of subjects with a reported
variable when different from the baseline. aSingle registry.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CVA ¼ cerebrovascular event;
ECMO ¼ extracorporeal membrane oxygenation; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention; RCT ¼ randomized controlled trial; STEMI ¼ ST-segment
elevation myocardial infarction; TIA ¼ transient ischemic attack.

tremendous efforts in performing such trials while
simultaneously capturing data on all patients in registries. To accomplish this, we must simplify the
enrollment process through efforts such as community consent and decreasing the risk of patient
exposure by using adaptive clinical trial designs.28
Our analysis demonstrates most RCT patients were
enrolled outside of the United States. Similarly, efforts to improve the inclusion of women and minorities in such trials are paramount. In our analysis,
most patients enrolled in RCTs were men, with fewer

DISCUSSION

women than in registries. Our analysis also demonstrated that despite the current efforts, women’s

Our study is the ﬁrst to compare characteristics of

enrollment in AMICS trials has not improved since the

patients presenting with CS enrolled in RCTs and

year 2000. This under-representation poses a chal-

registries. The main ﬁndings of our study include the

lenge to generalizing study results in clinical prac-

following: 1) a limited number of RCTs have been

tice. 29,30 Therefore, investigators and regulatory

conducted in patients with AMICS (14 since 2005),

bodies in the United States must allow an easier care

including just over 2,000 patients; 2) the majority of

process for such trials, including potentially a waiver

RCTs were performed in Europe; 3) women remain

or similar streamlining of informed consent, to ensure

under-represented in AMICS studies; 4) RCT patients

these trials apply to a broader population. Another

have fewer comorbidities and present with lower risk

potential solution to increasing the generalizability of

features; 5) RCT patients are more likely to get

AMICS studies is to use a standard deﬁnition of CS,

aggressive treatment with PCI, multivessel PCI, and

such as that proposed by the Society for Cardiovas-

ECMO; and 6) RCT patients had lower in-hospital and

cular Angiography and Interventions. 31 In doing so,

30-day mortality.

clinicians may be better equipped to compare
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F I G U R E 2 Pooled Analysis of the Effect Sizes of In-Hospital and 30-Day Mortality in RCTs and Registries

RCT ¼ randomized controlled trial.

outcomes and therapies in a heterogeneous shock

STUDY

cohort. Future RCTs and registries should similarly

describe differences in patient characteristics be-

LIMITATIONS. First,

we

only

aimed

to

delineate patients into speciﬁc shock phenotypes

tween AMICS enrolled in RCTs compared with reg-

based on etiology to provide better generalizability to

istries. A robust comparison could not be performed

clinicians.

because we lacked patient-level data. Second, data

Despite improvement in AMI treatment modalities

on multiorgan failure, circulatory failure, and other

and systems of care, the incidence of AMICS con-

types of shock that could be mixed with CS; the

tinues to rise.3,32 This increased incidence has been

need for vasoactive therapies; and the role of

attributed to an aging population, more comorbid-

noncardiac organ support were limited and not

ities, higher rates of multivessel disease, and an

systematically reported. Therefore, they could not

increasing rate of CS from non–ST-segment elevation

be further analyzed. Finally, data on speciﬁc MCS

myocardial infarction.3,33 These temporal changes are

devices could not be analyzed or reported as out-

important considerations for clinicians to keep in

comes because of the high prevalence of dedicated

mind as we apply the results of past and future RCTs

trials and registries that aimed to speciﬁcally study

to current practice. Lastly, it is important to highlight

those devices.

that the current steps leading to the diagnosis,
monitoring, and treatment of CS evolved from expert

CONCLUSIONS

opinion and observational data to help deﬁne best
practices. These efforts should not be dismissed

RCTs in AMICS tend to enroll fewer women and

because they have not been performed in an RCT.

lower-risk patients compared with registries. Patients

There is value in both RCT and registry data in AMICS.

enrolled in RCTs are more likely to receive treatment

Efforts to improve the quality of each and to incor-

with PCI and ECMO and have lower in-hospital and

porate newly gained knowledge into future trial de-

30-day mortality. Clinicians must remain practical in

signs are needed.

incorporating evidence from hard to perform RCTs
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C E NT R AL IL L U STR AT IO N Summary of the Study Results

Megaly, M. et al. J Am Coll Cardiol Intv. 2022;15(3):297–304.

AMI ¼ acute myocardial infarction; ECMO ¼ extracorporeal membrane oxygenation; PCI ¼ percutaneous coronary intervention; RCT ¼ randomized controlled trial.

and broadly applying data to different shock stages
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PERSPECTIVES
WHAT IS KNOWN? CS is a leading cause of in-hospital

more aggressive treatment and have lower in-hospital

mortality in patients with AMI. Enrollment of such pa-

and 30-day mortality.

tients into clinical trials is challenging and may not be
WHAT IS NEXT? Clinicians should remain practical

representative of real-world patients.

when universally applying data from RCTs to clinical
WHAT IS NEW? Patients enrolled in AMICS RCTs have

practice. Efforts to synthesize more data in AMICS, adopt

fewer comorbidities and present with lower risk features

adaptive clinical trial methods, and resolve ethical di-

than those in registries. Patients enrolled in RCTs get

lemmas in the consent process are needed to limit bias
and provide a broader application of future RCTs.
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